` BOT (Botanix Pharmaceuticals Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

BOT
vs
S&P/ASX 300

Over the past 12 months, BOT has significantly outperformed S&P/ASX 300, delivering a return of 32% compared to the S&P/ASX 300's 5% growth.

Stocks Performance
BOT vs S&P/ASX 300

Loading

Performance Gap
BOT vs S&P/ASX 300

Loading
BOT
S&P/ASX 300
Difference

Performance By Year
BOT vs S&P/ASX 300

Loading
BOT
S&P/ASX 300
Add Stock

Competitors Performance
Botanix Pharmaceuticals Ltd vs Peers

S&P/ASX 300
BOT
LLY
JNJ
NOVO B
ROG
Add Stock

Botanix Pharmaceuticals Ltd
Glance View

Market Cap
681.6m AUD
Industry
Pharmaceuticals

Botanix Pharmaceuticals Ltd. engages in the development of therapeutics for the treatment of skin diseases. The company is headquartered in Perth, Western Australia. The firm's product pipelines are based on drug delivery technology known as Permetrex. Its product pipeline consists of three clinical programs, which are using synthetic cannabidiol in the topical treatment of serious skin diseases and for antimicrobial applications. Its product pipeline includes BTX 1503 Gel, BTX 1702 Solution and BTX 1801 Ointment. Its BTX1503 Gel is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX 1702 Solution is used for the treatment of papulopustular rosacea. Its BTX 1801 Ointment is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus (MRSA). The firm also has a chemistry program to identify, synthesize and test chemical entities that are related to naturally occurring cannabinoids.

BOT Intrinsic Value
1.746 AUD
Undervaluation 79%
Intrinsic Value
Price
Back to Top